Sage Journals: Discover world-class research

Retricted access

Research article

First published 2022-3

Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease

Ji Yoon Kim, Shubha Bhat

Annals of Pharmacotherapy

Open access

Review article

First published 2019

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

Ágnes Milassin, Anna Fábián, Tamás Molnár

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2023

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

Rosanne W. Meijboom, Helga Gardarsdottir, Matthijs L. Becker [...]

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2025

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care

Hafsah Nabi, Kasper Yde Jensen, Rasmus Westermann [...]

Therapeutic Advances in Musculoskeletal Disease

Open access

Case report

First published 2022

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease

Shin Kashima, Koji Sawada, Kentaro Moriichi [...]

Therapeutic Advances in Drug Safety

Open access

Review article

First published 2023-1

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review

Naazish S. Bashir, Avery Hughes, Wendy J. Ungar

MDM Policy & Practice

Open access

Review article

First published 2019

The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111,an infliximab biosimilar,and in support of its use in all indications of the reference product

Joseph E. McClellan, Hugh D. Conlon, Michael W. Bolt [...]

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2021

Long-term effectiveness,safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

Sarah Fischer, Sarah Cohnen, Entcho Klenske [...]

Therapeutic Advances in Gastroenterology

Free access

Review article

First published 2016-5

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients

Jørgen Jahnsen

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2018

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease

Viktoria Bergqvist, Mohammad Kadivar, Daniel Molin [...]

Therapeutic Advances in Gastroenterology

Search results